Aptose Biosciences completed acquisition by Hanmi Pharmaceutical for C$2.41 per share
Aptose Biosciences consummated a plan of arrangement on June 30, 2026, under which HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., acquired all issued and outstanding common shares of Aptose not already held by Hanmi. Shareholders other than Hanmi and its affiliates received C$2.41 in cash per share, representing approximately USD $3,466,470 in aggregate consideration for 2,043,719 shares. The arrangement was approved by shareholders and the Alberta court on March 31, 2026; Aptose's common shares are expected to be delisted from the TSX on or about July 3, 2026, and the company intends to file Form 15 to terminate SEC reporting obligations.
Key facts
- Arrangement consideration: C$2.41 per common share
- Aggregate consideration paid: approximately USD $3,466,470 (C$4,925,362.79) for 2,043,719 common shares
- Hanmi owned 508,710 common shares (19.93% of outstanding) prior to effective time
- Effective date: June 30, 2026
- Court approval: March 31, 2026
- Expected TSX delisting: on or about July 3, 2026
- Form 15 filing planned to terminate SEC reporting obligations
Why it matters
Aptose is now a wholly owned subsidiary of Hanmi Pharmaceutical; the transaction extinguishes public equity ownership and removes the company from public markets, ending its independent status as a clinical-stage precision oncology company.
Developing story
- 15-12G
- 8-Kthis filing
Share
Derived from 8-K filed 2026-07-01. Not investment advice. View the source filing on SEC.gov →